SAGA expands with two diagnostics scientists to further accelerate launch of new products and services
LUND, Sweden — /March 30, 2020/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces the appointment of two new team members to significantly strengthen SAGA’s R&D team: Sofia Birkeälv, PhD as Molecular Diagnostics Scientist, NGS Lead, and Miguel Alcaide, PhD as Senior Molecular Diagnostics Scientist, dPCR.
Dr. Birkeälv is a graduate of the University of Cambridge, where she performed research at the Wellcome Sanger Institute and earned her PhD thesis on the “Genetic alterations defining human primary melanoma and mechanisms of immune evasion”. Sofia has solid knowledge of NGS assay design, applications, and bioinformatic analyses as well as industrial experience from both AstraZeneca and BioInvent. At SAGA, Sofia will be a key member of our R&D team with special focus on development and validation of new genomic assays.
Dr. Alcaide is an experienced molecular diagnostics scientist, with an in-depth expertise in liquid biopsy assay development for clinical use. Miguel has a broad academic background, most recently from the Simon Fraser University in Canada where he led development and evaluated the clinical utility of ctDNA in B-cell lymphoma and other solid tumors. Previously he was a post-doc scientist at University of British Columbia and Harvard University. Miguel’s role at SAGA will be to strengthen the R&D unit by developing new ultrasensitive dPCR assays and approaches.
We are very pleased to have been able to recruit Sofia and Miguel to strengthen our R&D team. Their expertise will help SAGA to develop ultrasensitive liquid biopsy solutions for personalized cancer diagnostics.
Lao Saal, co-founder and CEO, SAGA Diagnostics
Contact: CEO Lao Saal, MD PhD. email@example.com Phone: +46 (0) 733 01 7242
About SAGA Diagnostics AB
SAGA Diagnostics is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive “liquid biopsies” such as blood samples. SAGA helps pharmaceutical companies, scientists, and healthcare providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using these proprietary technologies gives SAGA unique ultrasensitivity, and provides the basis for optimal decision-making.